About
Exicure Inc (NASDAQ:XCUR) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Mar 25 2026
Exicure, Inc. Reports Full Year 2025 Financial Results
Feb 5 2026
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Jan 21 2026
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Dec 8 2025
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Financials
Revenue
$0
Market Cap
$25.62 M
EPS
-0.79
Translate